RecruitingNot ApplicableNCT06372158

Effects of Liposomal Encapsulation on Calcium Powder Absorption and Metabolism


Sponsor

National Yang Ming Chiao Tung University

Enrollment

20 participants

Start Date

Apr 8, 2024

Study Type

INTERVENTIONAL

Conditions

Summary

Compared with traditional calcium supplements, liposome calcium can increase the bioavailability of calcium and reduce the waste caused by gastric acid destruction of calcium. This allows calcium to be released slowly in the intestines, reducing the risk of indigestion or other side effects caused by excessive intake at one time. Liposomal calcium can be taken orally directly. It does not need to be dissolved in water before taking like other calcium supplements, making it more convenient to use. Based on the above advantages, liposomal calcium is a relatively safe and easy-to-absorb calcium supplement, suitable for long-term use, and can meet the body's demand for calcium. According to the recommendations of the World Health Organization, the daily calcium intake for adults should be 1000-1300 mg. In Taiwan, the seventh edition of the revised reference intake of dietary nutrients for Chinese people recommends that the daily intake for adults should be 1,000 mg. The calcium dose used in this study was 500 mg. The purpose was to explore whether the sustained-release characteristics of liposome coating technology can improve the absorption rate after consuming calcium powder and achieve better bioavailability. It is expected that microlipids made by lecithin can Lipid calcium powder increases its maintenance time in the blood, thereby increasing the supplementary effect of calcium, and is an alternative to calcium supplements.


Eligibility

Min Age: 20 YearsMax Age: 60 Years

Inclusion Criteria1

  • Adults aged 20-60 years old, without heart, liver, kidney, endocrine or major organic diseases (patient report), and able to fully cooperate with the experiment.

Exclusion Criteria13

  • Patients with renal insufficiency and dialysis
  • Cancer patients
  • Underweight (BMI#17) or obese (BMI#27)
  • Those taking medications for chronic diseases
  • Blood pressure systolic blood pressure # 130 mmHg or diastolic blood pressure # 85 mmHg
  • Fasting blood glucose # 100 mg/dL
  • Fasting triglycerides # 150 mg/dL, total cholesterol # 200 mg/dL
  • Have a history of vitamin C allergy
  • People suffering from mental illness
  • Pregnant and breastfeeding women
  • Patients with hemosiderosis
  • Kidney stone patients
  • Supplements for those who take calcium for a long time

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DIETARY_SUPPLEMENTStage 1

Number 1-10 :General vitamin C powder group (Contains 1500 mg Ca); Number 11-20: liposomal encapsulation Ca powder group (Contains 1500 mg of Ca and lecithin and is coated)

DIETARY_SUPPLEMENTStage 2

Number 11-20 :General vitamin C powder group (Contains 1500 mg Ca); Number 1-10: liposomal encapsulation Ca powder group (Contains 1500 mg of Ca and lecithin and is coated)


Locations(2)

National Yang Ming Chiao Tung University

Taipei, Beitou Dist., Taiwan

National Yang Ming Chiao Tung University

Taipei, Taiwan

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06372158


Related Trials